Clinical studies suggest that Helicobacter pylori may play a role in the pathogenesis of gastroduodenal ulcers in man but direct evidence of mucosal injury by this microorganism is still lacking. Paf-acether (paf) causes a number of disorders including ischaemic bowel necrosis and gastroduodenal ulceration. Since paf is produced by Escherichia coli, we investigated whether it could be synthesised by H pylori. Five H pylori isolates were coliected from antral biopsy specimens from patients with gastritis and duodenal ulcer and cultured with selective antibiotics. Colonies obtained from both blood agar and brucella broth medium were used. Paf was determined by platelet aggregation assay after ethanolic extraction and subsequent purification by high performance liquid chromatography. Paf was detected in H pylon in blood agar plates (680 (390) pg paf/lx 101 organisms) but not in bacteria cultured on brucelia broth medium. Supplementation of the latter medium with lyso paf and acetylCoA, two paf precursors present in high amounts in the mammalian intestine, induced paf production in three of five isolates. The platelet aggregating material extracted from H pylori exhibited biological and physiochemical characteristics identical to those of paf released from eukaryotic cells. These findings suggest that H pylori may add to the local production of paf in inflamed gastric mucosa.
Clinical studies suggest that Helicobacter pylori may play a role in the pathogenesis of gastroduodenal ulcers in man' but there is still no direct evidence of mucosal injury by the bacteria. Recently, Slomiany et al speculated on gastric mucosal damage by the bacteria, based on the mucolytic power of H pyloni in vitro.2 It has also been suggested that the lower relapse rate and superior microscopically observed healing in duodenal ulcer patients treated with bismuth or antibiotics, or both, are due to the disappearance of H pylon after this therapy.3 In addition, Esplugues et al suggested that the local release of paf-acether (paf) may account for the gastric and mucosal damage that is associated with colonisation with H pyloni.4 Paf (first described as platelet activating factor), identified as 1-O-alkyl-2-O acetyl sn-glycero-3-phosphocholine,'-I is synthesised by a wide variety of human cells including neutrophils, monocytes, macrophages, platelets, eosinophils, and vascular endothelial cells. 8 This potent inflammatory mediator can produce severe pathological changes in various organs ' and, among its numerous harmful effects, causes shock,'" gastric ulceration," and ischaemic bowel necrosis.'2 Since paf has recently been shown to be produced by Escherichia coli,"14 we investigated whether several H pylon isolates, collected from antral biopsy specimens of patients with gastritis and duodenal ulcer, could produce pafin vitro. This could be ofimportance in light of the role ofH pylori in the development of gastritis and peptic ulcer.
Materials and methods

REAGENTS
The following reagents were used: BN 52021: Figure 1 indicate that the exogenous precursors enhanced paf synthesis appreciably in three of five isolates ofH pylori on brucella broth medium. The combination of acetyl-CoA and lyso paf caused a twofold increase in paf production, when compared with bacteria supplemented with lyso paf alone. Acetyl-CoA alone did not stimulate paf formation. One representative kinetic experiment of paf production in brucella broth medium is shown in Figure 2 . In the presence of exogenous paf precursors, paf production began after 20 minutes, reached a maximum at 30 minutes, and decreased thereafter.
HISTOPATHOLOGICAL OBSERVATIONS
All patients had active chronic gastritis since increased numbers of mononuclear and polymorphonuclear leukocytes were found in the superficial or glandular epithelium.
PAF CONTENT OF BIOPSY SPECIMENS
No biopsy specimens (n=5) from the patients' stomachs contained paf but, interestingly, high amount of lyso paf (mean (SEM) (1 02) ng/ mg tissue) and A-A-GPC (mean (SEM) 121-6 (14-7) ng/mg tissue) were present.
STRUCTURAL ANALYSIS OF PAF
The platelet aggregating substance was indistinguishable from synthetic 1-O-alkly-2-acetyl sn-3-phosphocholine by the following physicochemical and biological criteria (Fig 3): (1) It induced aggregation of washed rabbit platelets that were refractory to adenosine diphosphate and arachidonic acid/thromboxane A2; (2) During high performance liquid chromatographic analysis, the platelet aggregating activity was eluted from 18 to 21 minutes between sphingomyelin and lysophosphatidylcholinethat is, a similar retention time to that of synthetic paf; Helicobacter pylori (I x 10' organismslml) were incubated in saline and bovine serum albumin at 37C, for indicated time intervals, alone (a) or in the presence ofo i mM lyso paf(O) or0 I mM lyso paf+0 I mM acetyl-CoA (a). Lipids were extracted, submitted to high performance liquid chromatography, and pafcontent was assayed as indicated in Materials and methods. Results are expressed in pgpafll x 106 organisms. One representative experiment out ofthree is shown.
(3) The platelet aggregation was completely inhibited by the paf antagonists BN 52021 (0 1 mM), CV 3988, and L 652,731 (the two latter not shown); (4) For further characterisation of the platelet aggregating molecule, we used lipase from R arrhizus (100 ,ug/ml), which hydrolyses exclusively the fatty acid ester bond at the 1-position of tri-and phosphoglycerides, and phospholipase A2 (10 [tg/ml), which specifically cleaves the acyl chain at the 2-position. The lack of effect of lipase from R arrhizus and the sensitivity to phospholipase A2 of the platelet aggregating factor recovered from H pylori are in agreement with a I-alkyl-2-acyl-3-glycerophospholipid structure.
Discussion
This is the first report of the synthesis of paf, an endogenous proinflammatory mediator which is one of the most potent ulcerogens of gastrointestinal tract," by H pylon, a bacterium associated with the pathogenesis of duodenal ulcer and acute gastritis in man.' Given the numerous substances that can activate platelets, it was necessary to show that the platelet aggregating material produced by H pylori was paf. To do this we used several experimental criteria to characterise and distinguish it from arachidonic acid, prostaglandin, collagen, thrombin or adenosine diphosphate, as described in the results sections. These data show that the H pylori generated material was paf.
An interesting point is the production ofpafin H pylon colonies on blood agar medium. We could not obtain paf in liquid medium. One interpretation is that paf results from the bioconversion of paf precursors present in the culture media. Indeed, micromolar concentrations of lyso paf were detected in horse blood agar and supplementation of saline with synthetic lyso paf stimulated paf production from H pyloni. a low bacterial concentration (5 x105 to lX 106 cells). By comparison, we showed paf production from E coli using lx 109 bacteria/ml.'3 We also speculate that liquid medium is not optimal for H pylori growth. 3 In addition, these data may not reflect the magnitude of paf generation by bacteria in situ. Another explanation would be a paf degradation in the liquid medium by an acetylhydrolase, immediately after its release, as reported in some eukaryotic cells."4 The fact that in kinetic experiments no paf was detected after 30 minutes incubation, could indicate the latter mechanism.
We were unable to detect paf in lipids from human biopsy specimens, a result that may be explained by their low weight. When three gastric biopsy specimens (15-20 mg) were extracted together (n=2), small amounts of paf could be detected (5-10 pg/mg tissue). This observation was similar to that of Eliakim et al,2" who studied paf release from rectal mucosal biopsy specimens obtained from patients with active ulcerative colitis. By contrast, we detected in gastric biopsy specimens high amounts of lyso paf and A-A-GPC, that could be used as precursor for paf by H pylori. The latter microorganism possesses phospholipase A2 activity26 (the enzyme that cleaves A-A-GPC into lyso paf) and, as shown in the present work, seems to be capable of acetylating exogenous lyso paf. There is also evidence to suggest that lyso paf resulting from the degradation of most eukaryotic cell membranes is abundant in the natural environment of the H pylori, thus providing the 'raw material' to be acetylated into paf.
The erratic behaviour of H pylori is striking since only three of five H pyloni isolates obtained from five patients could produce paf in the presence of exogenous precursors. Investigations on microbiological characterisation ofthese isolates are now in progress to attempt explaining this.
In conclusion, the present work shows that H pylori is able to generate paf in vitro and therefore possesses at least the final enzymatic pathways involved in paf synthesis. Because paf is a potent agonist in vivo, capable of inducing proinflammatory events such as cell chemotaxis, increase in vascular permeability, shock, gastric ulceration, and ischaemic bowel necrosis, it is tempting to speculate that its release from H pylori may play a part in the development and perpetuation of gastric injury.
